Search results
Showing 1261 to 1275 of 1422 results for primary care
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued Reference number: GID-TAG393
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
practice was unclear because of subsequent improvements in perioperative care such as better preoperative risk assessment and...
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs
NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.
Discontinued Reference number: GID-TAG368
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.